Drug intelligence / Profile preview

Onko-1

Development stage: Discontinued
Lead developer: Maxivax
Modality: Vaccines & Immunotherapeutics

Overview

Onko-1 is an investigational biological cancer vaccine being developed as a growth factor receptor–modulating therapy for solid tumors, with early clinical evaluation in gastric cancer. It is described as a biologic product targeting growth factor receptor pathways, aiming to modulate receptor signaling to inhibit tumor growth and potentially enhance antitumor immune responses in neoplastic diseases.[9][13] Development reached early clinical testing but the program has been discontinued globally, and detailed molecular target, construct design, and sponsor information have not been publicly disclosed.[9][13]

Targets

AXL (AXL receptor tyrosine kinase)

Beyond the preview

Go deeper on Onko-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Onko-1.

Explore the full profile